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Topical application of single doses of leukotriene R., 
(5-500 ng) under occlusion to the skin of normal vol-
unteers and to the clinically normal skin of patients with 
untreated stable plaque psoriasis caused an inflamma-
tory reaction lasting several days . Histologically, in-
traepidermal neutrophil microabscesses were seen in 
both groups following 50 ng applications of leukotriene 
B,., but there were significantly fewer intraepidermal 
neutrophils in the psoriatic than in the normal subjects. 
Nine repeated daily applications of leukotriene B,. (50 
ng) to the same site were associated with a reduction of 
the visible inflammatory response in both volunteer 
groups, although application of a single 50 ng dose of 
leukotriene B,. to an adjacent, previously untreated site 
at the e nd of the multiple dose experiments elicited acute 
erythema and edema. Histologically, there were signif-
icantly fewer intraepidermal neutrophils in biopsies 
from sites to which 9 applications of leukotriene B,. were 
made than in sites to which 1 dose had been applied at 
the e nd of the multiple-dose experiments in both pso-
riatic and normal volunteers. Therefore, repeated ap-
plication of Ieukotriene R, is associated with decreased 
res ponsiveness which is due to a local mechanism in the 
repeatedly treated skin. No subject developed psoriasis 
following single or multiple applications of leukotriene 
B,., suggesting that the production of leukotriene B, in 
t he epidermis is unlikely to be a primary pathogenic 
event in this disease. 
The a rachidonic acid lipoxygenase metabo lite, leukotri ene 
B 4 (58, 12R-dihydroxy-6, 14-cis-8, 10-trans-eicosatetraenoic 
acid, L TB4) is a potent neut rop hil chemotactic substance in 
v i t r o [1 ,2 ] a nd it has been shown to e lic it neutrophil infilt rates 
on intradermal injection in huma n ski n [3,4 ]. L TB.,-like ma-
teria l has been identified in extracts of chamber fluid and scale 
from psoriatic s kin les ions [5- 7] a nd it has t herefore been 
proposed t hat it may p lay a role in t he pathogenesis of t he 
intraepiderma l neutrop hil infil t rate t hat has been reported [8] 
to be one of the earliest cha nges in t he evo lution of a psoriatic 
lesion . Recently it was s hown [9] t hat s ingle top ica l applications 
of L TB, to t he s kin of norma l volunteers produce dose-re lated 
erythema a nd swe llin g. The reactions were cha racterized his-
tologica lly by in traepide rma l neutrop hil microabscesses a nd it 
was suggested that t hese cha n ges might represent a model of 
t h e inflammatory eve nts in psoriasis. The intraepidermal mi-
croabscesses were most pro min ent 24 h afte r application of 
L TB4 but were no longe r eviden t in 48- h or later biopsies, a nd 
epidermal hype rplas ia was not a s ignifi cant histo logic feature 
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at a ny stage up to 7 days. It was therefore considered t hat 
repeated applications of L TB, to t he same site might s imulate 
t he pathogenic events in psorias is more closely than single 
applications a nd might induce t he clinical and histologic fea -
tures of a psoriatic lesio n. In t his study t he effects of single and 
mul t iple app lications of L TB, to the skin of norma l volunteers 
a nd to t he c linically norma l sk in of psoriatic patients were 
t herefore determined . 
METHOD 
Dose Response Studies 
The expe riments were approved by the Institute Ethical Committee, 
and all volunteers gave in fo rmed consent. Twelve patients (aged 17- 65 
years) with stable plaque psoriasis involving 10- 30% of the body 
surface, and 12 healthy volunteers (aged 21- 49 years), studies in 7 of 
whom having been reported previously [9], participated. The 12 pa-
t ients had had no treatment fo r their psoriasis for at least 2 weeks 
before the start of and during the experiment. They were a lso receiving 
no oral medication. 
L TB, (supplied by Dr. J . Rokach, Merck Frosst, Canada) was applied 
t.o the flexor surface of the forearm of the psoriatic patients (clinically 
uninvolved skin) and normal subjects in the following quantities: 0.5, 
1, 10, 50, 100, and 500 ng. All sites were occluded for 6 h, and t he 
maximum diameters of t he result ing visible reactions were recorded. 
The method has been described in detail previously [9]. 
Multiple LTB, Applications 
In preliminary experiments LTB, (10 ng) was applied to the same 
site on the flexor aspect of the forearm twice weekly for 2 weeks in 7 
normal volunteers (aged 21- 40 yea rs). Following application, the sites 
were occluded for 6 has described [9]. 
The study was then extended. L TB, applications were carried out 
on 5 healt hy volunteers and on the clinically uninvolved skin of 4 
untreated psoriatic patients (less than 20% body involvement) . L TB, 
(50 ng) was applied topically to the same 2 sites on the forearm of each 
subject dai ly for 5 consecutive days. Following a weekend break of 2 
days the same amount of L TB, was applied daily for a further 4 
consecutive days to each site. Together with the 9th pair of applications, 
L TB, (50 ng) was also app lied to a thi rd, previously un treated site on 
the forearm of each subject. On the l Oth day, 24 h after the previous 
appl ications, punch biopsies (3 mm in diameter) were taken under local 
anesthesia from one of the sites of multiple app lication and from the 
site of single application . The unbiopsied sites, which had received 
mul tip le applications of L TB,, were observed for subsequent develop-
ment of psoriasis. Biopsies were fixed in formalin and subjected to 
routine paraffin section, sta ining with hematoxylin and eosin, and 
exam ination by light microscopy. ln t. raepidermal neutrophils in the 
full width of each biopsy were counted and results were expressed as 
counts per lO high power (400x magni fication) fields (HPF). Mono-
nuclear cells in the dermis were counted over the full width of each 
biopsy at I HPF depth below the dermal-epidermal junction. Results 
were expressed as counts per 10 HPF. 
RESULTS 
Dose Response Studies 
The numbers of norma l and psoriatic subjects vis ibly reacting 
to each dose of LTB4 a re givr n in Table f. The reactions 
cons isted of erythematous swellings which were maximum at 
20- 48 h . In addition , 2 normal volunteers developed transien t 
vesicular or pustular reactions [9] and 1 psoriatic patient de-
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TABLE I. Mean maximum diameters of LTB, reaction in normal 
controls and psoriatic subjects 
LTB, (ng) Mean diameter No. of subjects (mm ±SO) responding 
Normal subjects (n = 12) 
5 2.0 ± 1.6 8 
10 3.0 ± 1.5 10 
50 4.6 ± 1.9 11 
100 5.9 ± 1.3 12 
500 8.0 ± 1.3 12 
Psorialics (n = 12) 
5 0.9 ± 1.6 4 
10 1.9 ± 2.0 7 
50 5.7 ± 1.5 12 
100 6.8 ± 1.5 12 
500 9.2 ± 1.9 12 
TABLE II. Mean epidermal neutrophil counts± SD per 10 HPF 
Topical L TB, applica-
tion 
Single Multiple 
Normal subjects (n = 5) 
Psoriatics (n = 4) 
t-testb 
282 ± 138 
85 ± 44 
p = 0.03 
HPF "' High-power fie lds. 
"Single vs multiple applications. 
b Normal subjects vs psoriatics. 
' Not significant. 
70 ± 85 
11 ± 10 
NS' 
Paired t-test' 
p = 0.03 
p = 0.05 
veloped a flaccid blister at 72 h at the 500-ng site. The swellings 
began to resolve at about 72 h and by the 7th day macular, 
brownish pigmentation with variable superficial scaling was 
seen. No persistent psoriasiform lesion was elicited in any 
subject. The mean maximum diameters of the reactions in both 
groups were dose related and are given in Table I. 
Multiple LTB, Applications 
In normal volunteers who received 10 ng L TB, twice weekly, 
an erythematous swelling had developed by 24 h after the first 
application . The lesions began to fade at about 72 h and 
continued to do so despite 3 further applications to the same 
s ite over the course of 2 weeks. None of the volunteers devel-
oped psoriasiform changes at the test site. 
In a ll normal and psoriatic subjects an erythematous swelling 
was visible 24 h after the first application of 50 ng LTB, to 
sites that were to receive multiple applications. Repeated ap-
plications of L TB, (50 ng) to the same site did not produce any 
visible increase in the severity of the inflammatory reactions. 
Instead, after about 72 h, the swellings began to subside and 
leave brownish erythematous macules with variable amounts 
of superficial scaling, in spite of continued application. On 
follow-up for 3 months none of the normal or psoriatic subjects 
showed any evidence of psoriasis in t he unbiopsied site that 
had received multiple applications of L TB,. There was no 
notable pain or itching at any stage of the experiments. 
When LTB, (50 ng) was applied in a single dose to a previ-
ously untreated site, at t he time of the 9th application to 
multiple-treatment sites, swelling and erythema were seen at 
24 h in all normal subjects and psoriatic patients. The visible 
reactions in the psoriatic and normal groups were similar. The 
histology of the acute lesions 24 h after single L TB, application 
showed variable numbers of polymorphonuclear leukocytes in 
subcorneal vacuoles . The mean neutrophil counts in the epi-
dermis in the normal and>psoriatic groups are shown in TaWe 
II. The dermis showed a perivascular polymorphonuclear and 
mononuclear cell infiltrate in all biopsies 24 h after single LTB, 
app lication. The mean mononuclear cell counts in the dermis 
for both groups of subjects are given in Table Ill. The nature 
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of the mononuclear cell infiltrate could not be established by 
the methods used. 
The histology of sites of repeated (X 9) LTB, applications 
showed a few neutrophils in the subcorneal layers, except in 1 
normal volunteer and 1 psoriatic subject in whom no neutro-
phils were seen in the epidermis. The mean neutrophil counts 
in the epidermis in both groups are given in Table II. In the 
dermis, all biopsies of multiple-application sites showed a su-
perficial perivascular infiltrate which was predominantly 
mononuclear. The mean mononuclear cell counts in the dermis 
after single and multiple L TB4 applications in both normal and 
psoriatic groups are given in Table III. 
DISCUSSION 
These results show that single topical applications of L TB. 
produce visible inflammatory responses in both normal and 
psoriatic skin. Fewer psoriatics than normal volunteers devel-
oped visible responses to the single 5 ng and 10 ng doses of 
L TB, whereas all subjects responded to the 100 and 500 ng 
doses (Table 1). Biopsies 24 h after application of single 50 ng 
doses of L TB, showed significantly fewer intraepidermal neu-
trophils in psoriatics than in normal volunteers (Table II). In 
view of the small numbers studied it is not possible to determine 
whether the apparently reduced ability of the psoriatics to 
produce a neutrophil infiltrate in response to topically applied 
L TB4 is a characteristic of psoriasis. In an in vivo study of 80 
psoriatics, variable neutrophil chemoattractant responses to 
casein and serum were obtained depending on the duration and 
activity of the psoriasis [10] . 
Repeated application of L TB. (50 ng) to the same site was 
unexpectedly not associated with a progressive increase in the 
visible inflammatory reaction either in psoriatics or normal 
volunteers. In addition, in normal and psoriatic volunteers 
there was a significant reduction in intraepidermal neutrophil 
numbers after 9 applications in comparison with counts after 
a single application (Table II). To our knowledge this decreased 
responsiveness following repeated administration of a neutro-
phil chemoattractant in vivo has not been described, although 
a diminished inflammatory response to arachidonic acid applied 
repeatedly to mouse ear has been reported [ll). 
Stimulated neutrophils are themselves capable of synthesiz-
ing LTB, [12). The reduced infiltration of neutrophils on 
continued exposure to L TB. in vivo may be brought about by 
an important control mechanism which prevents persistent and 
progressive neutrophil accumulation in tissues, in spite of con-
tinual release of L TB4 by the infiltrating neutrophils them-
selves. The nature of this mechanism has not been established. 
Concentrations of L TB, higher than those causing maximal 
migration cause decreased chemotactic responsiveness of neu-
trophils in vitro. Further increases in concentration ultimately 
prevent stimulated movement, a phenomenon which gives rise 
to the characteristic bell-shaped dose-response curves in in 
vitro chemotaxis experiments [2] . However it is unlikely that 
this phenomenon is responsible for the reduced in vivo neutro-
phil infiltration described above, because the total amount of 
L TB. applied in the multiple-dose experiments was less than 
TABLE lll. Mean dermal counts of mononuclear cells± SD per 10 
HPF 
Topical L TB, application 
Single Multiple 
Normal subjects (n = 5) 
Psoriatics (n = 4) 
t-Testb 
HPF = High-power fields. 
174 ± 37 
108 ± 42 
p = 0.04 
• Single vs multiple applications. 
1
' Normal subjects vs psoriatics. 
'Not significant. 
462 ± 277 
290 ± 88 
NS' 
Paired t·test' 
p = 0.05 
p = 0.02 
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500 ng, an amoun t which, if applied in 1 dose, gives a brisk 
i n flammatory reaction. In addit ion, t he decreased reactivity 
was noted wit h 10 ng doses of L TB, applied twice weekly. It is 
a lso unl ikely t hat decreased responsiveness of circulating neu-
t r ophils fo llowing the 9 applications of L TB, is an explan ation 
fo r t he desc ribed tolerance, because application of 1 dose of 
L TB, to a fresh, previously unt reated skin site at t he end of 
each mult iple-dose experiment elicited fl orid intraepidermal 
n e u t rophil in fi lt ration. This phenomenon was most clearly 
d e m onstrated in the normal volunteers (T able II ). There fore a 
local mechanism in t he skin repeatedly t reated with L TB, must 
accoun t fo r the reduced neutrophil in fi lt ration seen. Dimin-
is h ed percutaneous absorpt ion of the repeatedly applied L TB, 
appears to be an unl ikely explanation fo r t he decreased respon-
siveness, in view of the sign ifica nt ly increased dermal mono-
nuclear cell counts found after mult iple applications (T able 
III). 
No subject developed an overt psoriatic lesion at t he unbiop-
s ied sites of single or multiple L T B4 application, indicating 
t h at production of L T B. by t he epidermis is unl ikely to be a 
primary pathogenic event in psoriasis, at least in the group of 
patients studied. 
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